AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04917874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open Label Topical Beremagene Geperpavec (B-VEC)
Description: Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
Study NCT06517680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tight control management
Description: Patients will be seen every month for the first 3 months of follow-up During these consultations, shoulder pain and function will be assessed. Treatment adjustments (steroid injections, drugs and physiotherapy) will be proposed in line with predefined objectives.
Study NCT06517680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up
Description: Patients are monitored according to standard practice
Study NCT05349435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezagepras
Description: Investigational drug
Study NCT05349435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Description: Investigational drug
Study NCT06017102 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: esophagogastroduodenoscopy
Description: once
Study NCT06788249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine only
Description: The primary study intervention involves the administration of intravenous ketamine (0.5 mg/kg) over a 40-minute infusion. Ketamine, an NMDA receptor antagonist, has shown rapid antidepressant effects in individuals with treatment-resistant depression.
Study NCT06417411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: Daily use of low dose aspirin.
Study NCT06417411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: Daily use of low dose aspirin.
Study NCT05635565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized goal training
Description: This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
Study NCT05635565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized goal training with educational strategies
Description: This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
Study NCT06246357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PentixaFor
Description: \[68Ga\]Ga-PentixaFor will be injected intravenously approximately 60 minutes prior to scanning at a dose of 150 +/- 50 MBq (4 mCi +/- 1.4).
Study NCT05345665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echography
Description: Neuronal blockade anesthesia for elective surgery of the hand was performed with an only echography.
Study NCT05345665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echography and neurostimulation
Description: Neuronal blockade anesthesia for elective surgery of the hand was performed with both echography and neurostimulation.
Study NCT05345665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echography, neurostimulation and active mobilization
Description: Neuronal blockade anesthesia for elective surgery of the hand was performed with echography, neurostimulation, and active mobilization.
Study NCT05137821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er: YSGG laser
Description: Er: YSGG laser decontamination of infected implant surfaces to simulate peri-implantitis therapy
Study NCT05137821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no therapy
Description: new sealed implant without any surface treatment
Study NCT05157633 — intervention group
Intervention type: OTHER
Intervention: Controls
Description: questionnaire food scale: HME data collection of food survey
Study NCT05643508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (D) DWC202206
Description: Drug of DWC202206 A mg
Study NCT05643508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (D) DWC202206
Description: Drug of DWC202206 A mg
Study NCT05643508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (D) DWC202207
Description: Drug of DWC202207 B/C mg
Study NCT05643508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (D) DWC202207
Description: Drug of DWC202207 B/C mg
Study NCT05643508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (P) DWC202206
Description: Placebo of DWC202206 A mg
Study NCT05643508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (P) DWC202207
Description: Placebo of DWC202207 B/C mg
Study NCT05056974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421
Description: 10 mg/kg, weekly UB-421 during the 8-week
Study NCT05056974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: 10 mg/dose, twice a week for 8 weeks
Study NCT06509698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: STEP I: For the warm-up, the examiner will perform passive stretching exercises to maintain the range of motion. STEP II: The patient will receive the game instructions by the examiner. STEP III: The patient will play the Adventure games and Sport games including tennis, boxing and kicking. virtual reality (20 minutes) using Nintendo Wii®, Wii Fit game will be used to stimulate and reinforce the improvement of balance and gait and enhance the quality of life.(30) Balance game: Soccer Heading, Penguin Slides, Balance Bubble, Torso Twists, and Single Leg Stance. Motor function: Boxing, Kicking, Tennis and Bowling Aerobic Games: 2-P run, advanced step, Title city and Basic Run. Step IV: (cool-down): Same as step one.
Study NCT06509698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frenkel's exercise
Description: Frenkel's activities, which included learning how to turn around, sit down, and get up using a variety of commonplace objects like chairs, beds, or traces drawn on the floor, as well as learning how to walk with upper limb coordination. This is a typical workout regimen used in testing and rehabilitation centers. Patients engaged in the following activities, each activity time is 1.5 minutes
Study NCT04919564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL)
Description: Furosemide 2 mg/hour infusion for 12 hours since induction
Study NCT04919564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
Study NCT05326919 — intervention group
Intervention type: OTHER
Intervention: Biobanking
Description: For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.
Study NCT05952544 — intervention group
Intervention type: DRUG
Intervention: essential amino acids and keto-analogues supplementation
Description: very low protein diet plus essential amino acids and keto-analogues supplementation
Study NCT05952544 — intervention group
Intervention type: OTHER
Intervention: low protein diet
Description: patients were on low protein diet only
Study NCT05878626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
Study NCT05878626 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
Study NCT05044364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.
Description: Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.
Study NCT05044364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.
Description: Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.
Study NCT06486623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Black chokeberry extract in capsules with 18% standardization of the anthocyanins content
Description: Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan.
Study NCT06486623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chokeberry fiber in capsules
Description: Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan.
Study NCT06337552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FEED-FF
Description: 3-6 servings of any combination of the following fermented foods/day (from 1 week prior to treatment to approximately 12 weeks after the start of treatment): Yogurt, cottage cheese, kefir, kombucha, sauerkraut, and kimchi.
Study NCT06337552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SUC)
Description: Standard of Care (SUC) is the treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by health care professionals. Standard of Care will comprise general healthy eating handouts that describe typical healthy foods and the suggested level of servings per day.
Study NCT06464315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Substrate-Only Mapping without VT Induction
Description: In this arm, invasive maps will be constructed by annotating the latest deflection and peak frequency during voltage mapping of stable intrinsic rhythm to localize areas of slow conduction. Annotated algorithms are cleared by the FDA. No VT will be purposefully induced in this experimental arm.
Study NCT05009992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib
Description: Given PO
Study NCT05503953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSAVI
Description: Uptitation
Study NCT05503953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AGLS
Description: Uptitration
Study NCT05670977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study product plus collagen supplement
Description: The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
Study NCT05670977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Study product without collagen supplement
Description: The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
Study NCT04615871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
Study NCT06103110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Laser therapy using low level laser
Study NCT05191212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Cervical indocyanine green injection for the detection of sentinel lymph node
Study NCT05191212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: indocyanine green
Description: Cervical indocyanine green injection for the detection of sentinel lymph node
Study NCT04621747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Battery of neurophysiological explorations
Description: Visit 1: Biometry collection: gender, age, weight, height, eye colour.~* Questionnaires : the State and Trait Anxiety Inventory and the Pain Sensitivity~* Threshold of unpleasant light brightness, mechanical sensitivity threshold (von Frey hair).~* Training to estimate unpleasantness Under nociceptive and tickling stimuli, to use the handgrip.~* Mechanical pain threshold (electronic von Frey), heat pain threshold (Medoc Pathway).~* 48 stimulations applied to the back skin, following a predetermined plan with 12 different pathways, imbricated with 4 different speeds of movement.~Visit 2 (1 to 8 days later) :~* 42 stimulations applied to the back skin, to test the effect of stimulation intensity, the side of application, continuity break of the contact, and distraction by other cutaneous stimuli. The stimuli will follow the best paradigm as identified at the previous visit.~* 12 stimulations applied to forearm, cheeks, lower limbs, also testing the effect of hairiness.
Study NCT05057988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief class
Description: The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
Study NCT05953064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DHA-NAT
Description: Endogenous metabolite of omega-3 fatty acid docosahexaenoic acid
Study NCT05953064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle control (H2O) for the intervention used in the experimental arm (DHA-NAT).
Study NCT05654415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Each enrolled patient will be subjected to two nap EEG recordings receiving in one occasion the melatonin-based solution under study at a dosage of 5 mg
Study NCT05654415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprivation
Description: Each enrolled patient will be subjected to two nap EEG recordings,in one they will be subjected to sleep deprivation
Study NCT04734873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 2 mg/kg + SOC
Description: IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
Study NCT04734873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 1 mg/kg + SOC
Description: IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
Study NCT04734873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SOC
Description: IV placebo plus standard of care
Study NCT04876339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait rehabilitation with sonification
Description: The sonification system is composed by 2 inertial sensors, a computer and a pair of bluetooth headphones connected with the computer. The sensors will be placed one per leg at the ankle and connected with Matlab software. An home-made ad-hoc software associates patient's movements with music patterns. The patient's natural rhythm is detected and used at the beginning of the intervention. The first part of each exercise is supported by a pre-recorded chord progression with a click on the background. In the second part (sonification approach) the software notices and records the contact of the heel with the ground. Each contact activates musical stimuli listened to via headphones. The steps succession will build a regular and predictable musical progression in relation to the correct sequence of steps. The exercises planned in this intervention are the same as those planned in the gait standard rehabilitation (see below).
Study NCT04876339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard gait rehabilitation (without sonification)
Description: The training will be carried out without any musical support. Exercises I Phase~1. Load shift in anteroposterior standing in tandem position, left foot forward (3 minutes exercise with a short break in the middle)~2. Load shift in anteroposterior standing in tandem position, right foot forward (3 minutes exercise with a short break in the middle)~3. Left foot swing (3 minutes exercise with a short break in the middle)~4. Right foot swing (3 minutes exercise with a short break in the middle)~5. March in place (3 minutes exercise with a short break in the middle) Exercises II phase (15 minutes): the patient will perform 14 minutes of walking with a 1 minute of break in the middle (7 minutes of walking, 1 minute rest, 7 minutes of walking). In the second part of walking the patient will be asked to slightly increase the pace of the step up to the maximum possible speed.
Study NCT04708990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delipid Extracorporeal Lipoprotein filter from Plasma
Description: As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
Study NCT05740787 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observation only
Study NCT06185920 — intervention group
Intervention type: OTHER
Intervention: Description of severe infection
Description: Description of severe infections treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.
Study NCT06464315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care Mapping/Imaging
Description: Conventional invasive scar (voltage) and electrical VT (entrainment, activation, pace) mapping will be used to guide VT ablation. Functional substrate mapping will not be used in this arm. VT will be induced using standard protocols.
Study NCT05309083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Walking Therapy (MBWT)
Description: MBWT will be a modified form of the typical Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking meditations and is acceptable for people with Parkinson disease and freezing of gait.
Study NCT04937699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-DAPT of Ticagrelor plus aspirin
Description: Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months
Study NCT04937699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential monotherapy of Ticagrelor and clopidogrel
Description: Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
Study NCT04894916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Diabetes Care Mobile (MDC-m)
Description: My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL), incorporates motivational strategies and access to an online patient support community, and provides literacy level-appropriate and tailored diabetes self-care information.
Study NCT05140382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4573
Description: AZD4573 will be given intravenously
Study NCT04607759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutraceutical
Description: Subjects will consume two capsules for eight weeks
Study NCT04906590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] PI-2620
Description: Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
Study NCT05170360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:
Description: 1. Assessment of smoking exposure:~   Serum cotinine will be measured by using serum cotinine ELISA kits~2. Assessment of heavy metal exposure:~   Lead and cadmium will be measured using Graphite Tube Atomizer.~3. Assessment of organophosphorus exposure:~   By measuring pseudocholinesterase level by spectrophotometer~4. Mutational analysis of the KRAS and BRAF genes:~the tissue samples will be used to determine the mutation in k-ras and BRAF genes by RCR